Tumor organoid-originated biomarkers predict immune response to PD-1 blockade

Cansu Cimen Bozkus; Nina Bhardwaj

doi:10.1016/j.ccell.2021.08.003

Tumor organoid-originated biomarkers predict immune response to PD-1 blockade

Cansu Cimen Bozkus, Nina Bhardwaj

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Despite the demonstrated efficacy and broad applicability of checkpoint blockade, the mechanisms by which it exerts its antitumor effects are incompletely understood. A recent article in Nature Medicine describes an ex vivo platform for assessing early responses to checkpoint blockade and the properties of tumor immune contexture in correlation to clinical responses.

Original language	English
Pages (from-to)	1187-1189
Number of pages	3
Journal	Cancer Cell
Volume	39
Issue number	9
DOIs	https://doi.org/10.1016/j.ccell.2021.08.003
State	Published - 13 Sep 2021

Access to Document

10.1016/j.ccell.2021.08.003

Cite this

@article{85025d9d27b249a2b85727c0cf930292,

title = "Tumor organoid-originated biomarkers predict immune response to PD-1 blockade",

abstract = "Despite the demonstrated efficacy and broad applicability of checkpoint blockade, the mechanisms by which it exerts its antitumor effects are incompletely understood. A recent article in Nature Medicine describes an ex vivo platform for assessing early responses to checkpoint blockade and the properties of tumor immune contexture in correlation to clinical responses.",

author = "{Cimen Bozkus}, Cansu and Nina Bhardwaj",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = sep,

day = "13",

doi = "10.1016/j.ccell.2021.08.003",

language = "English",

volume = "39",

pages = "1187--1189",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "9",

}

TY - JOUR

T1 - Tumor organoid-originated biomarkers predict immune response to PD-1 blockade

AU - Cimen Bozkus, Cansu

AU - Bhardwaj, Nina

PY - 2021/9/13

Y1 - 2021/9/13

N2 - Despite the demonstrated efficacy and broad applicability of checkpoint blockade, the mechanisms by which it exerts its antitumor effects are incompletely understood. A recent article in Nature Medicine describes an ex vivo platform for assessing early responses to checkpoint blockade and the properties of tumor immune contexture in correlation to clinical responses.

AB - Despite the demonstrated efficacy and broad applicability of checkpoint blockade, the mechanisms by which it exerts its antitumor effects are incompletely understood. A recent article in Nature Medicine describes an ex vivo platform for assessing early responses to checkpoint blockade and the properties of tumor immune contexture in correlation to clinical responses.

UR - http://www.scopus.com/inward/record.url?scp=85116957223&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2021.08.003

DO - 10.1016/j.ccell.2021.08.003

M3 - Article

C2 - 34478641

AN - SCOPUS:85116957223

SN - 1535-6108

VL - 39

SP - 1187

EP - 1189

JO - Cancer Cell

JF - Cancer Cell

IS - 9

ER -

Tumor organoid-originated biomarkers predict immune response to PD-1 blockade

Abstract

Access to Document

Fingerprint

Cite this